Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women

Harvard School of Public Health (HSPH)33,000 enrolled

Overview

This study is a secondary analysis of data collected in the Nurses' Health Study (NHS) that will evaluat the association between intake of sugar sweetened beverages (SSB), juice and artificially sweetened beverages in relation to biomarkers of hepatic function, lipid metabolism, inflammation and glycemic control.

The investigators will analyze cross-sectional data from 8,492 participants in the Nurses' Health Study who were free of diabetes and cardiovascular disease to evaluate the association between intake of sugar sweetened beverages (SSB), juice and artificially sweetened beverages (ASB) and biomarkers of hepatic function, lipid metabolism, inflammation and glycemic control. Biomarkers were measured from blood samples that were collected in 2 cycles, approximately 10 years apart. Specifically, multivariate linear regression will be used to assess the associations of SSB, ASB, and fruit juice intake with concentrations of fetuin-A, alanine transaminase, gamma-glutamyl transferase, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol, C-reactive protein (CRP), intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1), adiponectin, insulin, and hemoglobin A1c as well as total cholesterol/HDL-C ratio.

Study Type

OBSERVATIONAL

Enrollment

33,000

Conditions

Biomarkers

Interventions

Sugar sweetened beverage (SSB)OTHER

This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.

Eligibility

Sex: FEMALEMin age: 30 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: For the current study, we included participants who provided a blood sample and were previously selected as controls for nested case-control analyses of type 2 diabetes, coronary heart disease, stroke, colon cancer, colon polyps, pancreatic cancer, and breast cancer in the Nurse's Health Study. Exclusion Criteria: Participants with self-reported prevalent diabetes or cardiovascular disease (CVD) at blood draw were excluded. After exclusions, a total of 8,492 individuals (6,961 from cycle 1 and 1,531 from cycle 2) with valid beverage intake data were included in the current analysis.

Locations (1)

Harvard T.H. Chan School of Public Health

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Fetuin-A

Biomarkers of liver function

Time frame: Blood collection cycle 1 (1989-1990)

Fetuin-A

Biomarkers of liver function

Time frame: Blood collection cyle 2 (2000-2001)

Alanine transaminase

Biomarkers of liver function

Time frame: Blood collection cycle 1 (1989-1990)

Alanine transaminase

Biomarkers of liver function

Time frame: Blood collection cyle 2 (2000-2001)

Gamma-glutamyl transferase

Biomarkers of liver function

Time frame: Blood collection cycle 1 (1989-1990)

Gamma-glutamyl transferase

Biomarkers of liver function

Time frame: Blood collection cyle 2 (2000-2001)

Secondary Outcomes

Triglycerides

Biomarkers of lipid metabolism

Time frame: Blood collection cycle 1 (1989-1990)

Triglycerides

Biomarkers of lipid metabolism

Time frame: Blood collection cycle 2 (2000-2001)

High-density lipoprotein cholesterol (HDL-C)

Biomarkers of lipid metabolism

Time frame: Blood collection cycle 1 (1989-1990)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.